Neuland Laboratories

Neuland Laboratories delivered a record Q4 FY26 with revenue of ₹788.7 croreCurrent reported value: ₹788.7 crore. No comparable prior figure is available in the source record. (up 134.9% YoYCurrent reported value: 134.9% YoY. No comparable prior figure is available in the source record.), driven by commercial CDMO shipments and favorable exchange rates. EBITDA margin surged to 40.5%Current reported value: 40.5%. No comparable prior figure is available in the source record., partly due to lumpy revenue timing. PAT jumped to ₹212.5 croreCurrent reported value: ₹212.5 crore. No comparable prior figure is available in the source record. from ₹27.7 crore last year. Full-year revenue grew 37%Current reported value: 37%. No comparable prior figure is available in the source record. to ₹2,053 crore, with EBITDA margin expanding to 29.4%. Management reiterated that quarterly lumpiness will persist but long-term growth visibility remains strong, anchored by commercial molecules and peptide investments. The peptide facility is on track for July commissioning. Key risks include demand variability, customer ordering patterns, and geopolitical supply chain disruptions. The company maintains a disciplined capex approach and expects working capital to normalize in FY27.